Notice of an Extraordinary General Meeting

The report describes encouraging clinical signals from Radspherin® studies and the start of a randomized phase 2 ovarian cancer study, with the first patient treated in October 2024. The company received FDA Fast Track designation for the ovarian cancer indication and renewed its GMP manufacturing authorization. It also entered a laboratory collaboration with ARTBIO and raised NOK 130 million through an oversubscribed private placement before listing on Euronext Growth Oslo.